Modeling the effects of omalizumab over 5 years among patients with moderate-to-severe persistent allergic asthma

References

• Xolair (omalizumab) for Subcutaneous Use, US package insert. South San Francisco, CA: Genentech, Inc, July 2008
   Google Scholar
• Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. Bethesda, MD: U.S. Department of Health and Human Services; National Institutes of Health; National Heart, Lung, and Blood Institute; National Asthma Education and Prevention Program, 2007
   Google Scholar
• Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001;108:184-90
   PubMed Web of Science ®Google Scholar
• Milgrom H, Berger W, Nayak A, et al. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics 2001;108:E36
   PubMed Web of Science ®Google Scholar
• Soler M, Matz J, Townley R, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001;18:254-61
   PubMed Web of Science ®Google Scholar
• Holgate ST, Chuchalin AG, Hebert J, et al. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy 2004;34:632-8
   PubMed Web of Science ®Google Scholar
• Vignola AM, Humbert M, Bousquet J, et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy. 2004;59:709-17
   PubMed Web of Science ®Google Scholar
• Humbert M, Beasley R, Ayres J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005;60:309-16
   PubMed Web of Science ®Google Scholar
• Ayres JG, Higgins B, Chilvers ER, et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. Allergy 2004;59:701-8
   PubMed Web of Science ®Google Scholar
• Buhl R, Soler M, Matz J, et al. Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma. Eur Respir J. 2002;20:73-8
   PubMed Web of Science ®Google Scholar
• Lanier BQ, Corren J, Lumry W, et al. Omalizumab is effective in the long-term control of severe allergic asthma. Ann Allergy Asthma Immunol. 2003;91:154-9
   PubMed Web of Science ®Google Scholar
• Bousquet J, Cabrera P, Berkman N, et al. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy 2005;60:302-8
   PubMed Web of Science ®Google Scholar
• Walker S, Monteil M, Phelan K, et al. Anti-IgE for chronic asthma in adults and children. Cochrane Database Syst Rev 2006;(2):CD003559
   PubMed Web of Science ®Google Scholar
• Details about the construction, calibration, and validation of the Archimedes Asthma Model were presented at the International Conference from the American Thoracic Society, New Orleans, LA, May 14-19, 2010. They will also be published in a manuscript, which is under development: Schlender A, Grossman HL, Alperin P, Sutherland ER. The construction, calibration, and validation of an epidemiological computer model of chronic asthma
   Google Scholar
• Mandelblatt JS, Cronin KA, Bailey S, et al. Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms. Ann Intern Med 2009;151:738-47
   PubMed Web of Science ®Google Scholar
• Zauber AG, Lansdorp-Vogelaar I, Knudsen AB, et al. Evaluating test strategies for colorectal cancer screening: a decision analysis for the U.S. Preventive Services Task Force. Ann Intern Med 2008;149:659-69
   Google Scholar
• Dudl RJ, Wang MC, Wong M, et al. Preventing myocardial infarction and stroke with a simplified bundle of cardioprotective medications. Am J Manag Care 2009;15:e88-94
   PubMed Web of Science ®Google Scholar
• Paltiel AD, Fuhlbrigge AL, Kitch BT, et al. Cost-effectiveness of inhaled corticosteroids in adults with mild-to-moderate asthma: results from the asthma policy model. J Allergy Clin Immunol 2001;108:39-46
   PubMed Web of Science ®Google Scholar
• Kahn R, Alperin P, Eddy D, et al. Age at initiation and frequency of screening to detect type 2 diabetes: a cost-effectiveness analysis. Lancet 2010;375:1365-74
   PubMed Web of Science ®Google Scholar
• Eddy DM, Schlessinger L, Kahn R. Clinical outcomes and cost-effectiveness of strategies for managing people at high risk for diabetes. Ann Intern Med 2005;143:251-64
   PubMed Web of Science ®Google Scholar
• Eddy DM, Pawlson LG, Schaaf D, et al. The potential effects of HEDIS performance measures on the quality of care. Health Aff 2008;27:1429-41
   Web of Science ®Google Scholar
• Kahn R, Robertson RM, Smith R, et al. The impact of prevention on reducing the burden of cardiovascular disease. Circulation 2008;118:576-85
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). National Center for Environmental Health (NCEH). National Asthma Survey (NAS), 2003-2004. Available at: http://www.cdc.gov/nchs/slaits/nas.htm [Last accessed 11 December 2009]
   Google Scholar
• Centers for Disease Control and Prevention (CDC). National Center for Health Statistics (NCHS). National Hospital Discharge Survey (NHDS), 2004-2006. Available at: http://www.cdc.gov/nchs/nhds.htm [Last accessed 14 December 2009]
   Google Scholar
• Tattersfield AE, Postma DS, Barnes PJ, et al. Exacerbations of asthma: a descriptive study of 425 severe exacerbations. Am J Respir Crit Care Med 1999;160:594-9
   PubMed Web of Science ®Google Scholar
• Lange P, Parner J, Vestbo J, et al. A 15-year follow-up study of ventilatory function in adults with asthma. N Engl J Med 1998;339:1194-200
   PubMed Web of Science ®Google Scholar
• Carranza Rosenzweig JR, Edwards L, Lincourt W, et al. The relationship between health-related quality of life, lung function and daily symptoms in patients with persistent asthma. Respir Med 2004;98:1157-65
   PubMed Web of Science ®Google Scholar
• McFadden ER Jr. Acute severe asthma. Am J Respir Crit Care Med 2003;168:740-59
   PubMed Web of Science ®Google Scholar
• Cerveri I, Locatelli F, Zoia MC, et al. International variations in asthma treatment compliance. Eur Respir J 1999;14:288-294
   PubMed Web of Science ®Google Scholar
• Martin TG, Elenbaas RM, Pingleton SH. Failure of peak expiratory flow rate to predict hospital admission in acute asthma. Ann Emerg Med 1982;11:466-70
   PubMed Web of Science ®Google Scholar
• Adams NP, Bestall JB, Malouf R, et al. Inhaled beclomethasone versus placebo for chronic asthma. Cochrane Database Syst Rev 2005;(1):CD002738
   PubMed Web of Science ®Google Scholar
• Ni Chroinin M, Greenstone IR, Danish A, et al. Long-acting beta2-agonists versus placebo in addition to inhaled corticosteroids in children and adults with chronic asthma. Cochrane Database Syst Rev 2005;(4):CD005535
   PubMed Web of Science ®Google Scholar
• Rowe BH, Spooner CH, Ducharme FM, et al. Corticosteroids for preventing relapse following acute exacerbations of asthma. Cochrane Database Syst Rev 2007;(3):CD000195
   PubMed Web of Science ®Google Scholar
• Powell H, Gibson PG. High dose versus low dose inhaled corticosteroid as initial starting dose for asthma in adults and children. Cochrane Database Syst Rev 2004;(2):CD004109
   PubMed Web of Science ®Google Scholar
• Haselkorn T, Borish L, Miller DP, et al. High prevalence of skin test positivity in severe or difficult-to-treat asthma. J Asthma 2006;43:745-52
   PubMed Web of Science ®Google Scholar
• Hawkins G, McMahon AD, Twaddle S, et al. Stepping down inhaled corticosteroids in asthma: randomised controlled trial. BMJ 2003;326:1115
   PubMed Web of Science ®Google Scholar
• Bousquet J, Wenzel S, Holgate S, et al. Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma. Chest 2004;125:1378-86
   PubMed Web of Science ®Google Scholar
• Bousquet J, Rabe K, Humbert M, et al. Predicting and evaluating response to omalizumab in patients with severe allergic asthma. Respir Med 2007;10:1483-92
   Google Scholar
• Ayre G, Fox H, Chen H, et al. Evaluating response to omalizumab (anti-IgE) in clinical practice. Poster presented at the European Respiratory Society Meeting, 17-21 September 2005, Copenhagen
   Google Scholar
• Bousquet J, Cabrera P, Berkman N, et al. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy 2005;60:302-8
   PubMed Web of Science ®Google Scholar
• Rao CR. The theory of least squares when the parameters are stochastic and its application to the analysis of growth curves. Biometrika 1965;52:447-58
   PubMed Web of Science ®Google Scholar
• Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics 1982;38:963-74
   PubMed Web of Science ®Google Scholar
• Bevington P, Robinson D. Data Reduction and Error Analysis for the Physical Sciences. New York: McGraw Hill, 2002
   Google Scholar
• Dahl R. Systemic side effects of inhaled corticosteroids in patients with asthma. Respir Med 2006;100:1307-17
   PubMed Web of Science ®Google Scholar
• Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy: a systematic review and meta-analysis. Arch Intern Med 1999;159:941-55
   PubMed Web of Science ®Google Scholar
• Walsh LJ, Wong CA, Oborne J, et al. Adverse effects of oral corticosteroids in relation to dose in patients with lung disease. Thorax 2001;56:279-84
   PubMed Web of Science ®Google Scholar
• Condemi JJ, Hamilos DL, Hanania NA, et al. Efficacy and safety of omalizumab in patients with moderate-to-severe persistent asthma poorly controlled on high-dose inhaled corticosteroids and long-acting beta-agonists—results of a phase IIIb randomized controlled trial type: late breaker. Am J Respir Crit Care Med 2010;181:A6840
   Google Scholar
• Gergen PJ, Arbes SJ Jr, Calatroni A, et al. Total IgE levels and asthma prevalence in the US population: results from the National Health and Nutrition Examination Survey 2005-2006. J Allergy Clin Immunol 2009;124:447-53
   PubMed Web of Science ®Google Scholar